PDB rendering based on 1esl.
|Symbols||; CD62E; ELAM; ELAM1; ESEL; LECAM2|
|External IDs||ChEMBL: GeneCards:|
|RNA expression pattern|
E-selectin, also known as CD62 antigen-like family member E (CD62E), endothelial-leukocyte adhesion molecule 1 (ELAM-1), or leukocyte-endothelial cell adhesion molecule 2 (LECAM2), is a cell adhesion molecule expressed only on endothelial cells activated by cytokines. Like other selectins, it plays an important part in inflammation. In humans, E-selectin is encoded by the SELE gene.
- 1 Structure
- 2 Gene and regulation
- 3 Ligands
- 4 Function
- 5 Pathological relevance
- 6 References
- 7 External links
E selectin has a cassette structure: an N-terminal, C-type lectin domain, an EGF (epidermal-growth-factor)-like domain, 6 Sushi domain (SCR repeat) units, a transmembrane domain (TM) and an intracellular cytoplasmic tail (cyto). The three-dimensional structure of the ligand-binding region of human E-selectin has been determined at 2.0 Å resolution in 1994. The structure reveals limited contact between the two domains and a coordination of Ca2+ not predicted from other C-type lectins. Structure/function analysis indicates a defined region and specific amino-acid side chains that may be involved in ligand binding. The E-selectin bound to sialyl-LewisX (SLeX; NeuNAcα2,3Galβ1,4[Fucα1,3]GlcNAc) tetrasaccharide was solved in 2000.
Gene and regulation
In humans, E-selectin is encoded by the SELE gene. Its C-type lectin domain, EGF-like, SCR repeats, and transmembrane domains are each encoded by separate exons, whereas the E-selectin cytosolic domain derives from two exons. The E-selectin locus flanks the L-selectin locus on chromosome 1.
Different from P-selectin, which is stored in vesicles called Weibel-Palade bodies, E-selectin is not stored in the cell and has to be transcribed, translated, and transported to the cell surface. The production of E-selectin is stimulated by the expression of P-selectin which in turn, is stimulated by tumor necrosis factor α (TNFα), interleukin-1 (IL-1) and lipopolysaccharide (LPS). It takes about two hours, after cytokine recognition, for E-selectin to be expressed on the endothelial cell's surface. Maximal expression of E-selectin occurs around 6–12 hours after cytokine stimulation, and levels returns to baseline within 24 hours.
Shear forces are also found to affect E-selectin expression. A high laminar shear enhances acute endothelial cell response to interleukin-1β in naïve or shear-conditioned endothelial cells as may be found in the pathological setting of ischemia/reperfusion injury while conferring rapid E-selectin down regulation to protect against chronic inflammation.
Phytoestrogens, plant compounds with estrogen-like biological activity, such as genistein, formononetin, biochanin A and daidzein, as well as a mixture of these phytoestrogens were found able to reduce E-selectin as well as VCAM-1 and ICAM-1 on cell surface and in culture supernatant.
E-selectin recognizes and binds to sialylated carbohydrates present on the surface proteins of certain leukocytes. E-selectin ligands are expressed by neutrophils, monocytes, eosinophils, memory-effector T-like lymphocytes, and natural killer cells. Each of these cell types is found in acute and chronic inflammatory sites in association with expression of E-selectin, thus implicating E-selectin in the recruitment of these cells to such inflammatory sites.
The glycoprotein ESL-1, present on neutrophils and myeloid cells, was the first counter-receptor for E-selectin to be described. It is a variant of the tyrosine kinase FGF glycoreceptor, raising the possibility that its binding to E-selectin is involved in initiating signaling in the bound cells
P-selectin glycoprotein ligand-1 (PSGL-1) derived from human neutrophils is also a high-efficiency ligand for endothelium-expressed E-selectin under flow. It mediates the rolling of leukocytes on the activated endothelium surrounding an inflamed tissue.
Both ESL-1 and PSGL-1 should bear sialyl Lewis a/x in order to bind E/P-selectins.
E-selectin is found to mediate the adhesion of tumor cells to endothelial cells, by binding to E-selectin ligands on the tumor cells. E-selectin ligands also play a role in cancer metastasis. The role of these two E-selectin ligands in metastasis in vivo is poorly defined and remains to be firmly demonstrated. PSGL-1 was detected on the surfaces of bone-metastatic prostate tumor cells, suggesting that it may have a functional role in the bone tropism of prostate tumor cells.
In cancer cells, CD44, death receptor-3 (DR3), LAMP1, and LAMP2 were identified as E-selectin ligands present on colon cancer cells., and CD44v, Mac2-BP, and gangliosides were identified as E-selectin ligands present on breast cancer cells.
On human neutrophils the glycosphingolipid NeuAcα2-3Galβ1-4GlcNAcβ1-3[Galβ1-4(Fucα1-3)GlcNAcβ1-3]2[Galβ1-4GlcNAcβ1-3]2Galβ1-4GlcβCer (and closely related structures) are functional E-selectin receptors.
Role in inflammation
During inflammation, E-selectin plays an important part in recruiting leukocytes to the site of injury. The local release of cytokines IL-1 and TNF-α by damaged cells induces the over-expression of E-selectin on endothelial cells of nearby blood vessels. Leukocytes in the blood expressing the correct ligand will bind with low affinity to E-selectin, also under the shear stress of blood flow, causing the leukocytes to "roll" along the internal surface of the blood vessel as temporary interactions are made and broken.
As the inflammatory response progresses, chemokines released by injured tissue enter the blood vessels and activate the rolling leukocytes, which are now able to tightly bind to the endothelial surface and begin making their way into the tissue.
Role in Cancer
Cancer cells are able to infiltrate the inﬂammatory system by interacting with selectins. E-selectin mediates the adhesion of tumor cells to endothelial cells, by binding to E-selectin ligands expressed by neutrophils, monocytes, eosinophils, memory-effector T-like lymphocytes, natural killer cells or cancer cells. This interaction is associated with metastatic dissemination. However, the initial interaction between selectins and cancer cells are not sufficient to confer metastasis. As for leukocytes during inflammation, cancer cells bound to E-selectin are released into the circulation unless secondary adhesion mechanisms are activated. In some cases, cancer cells can interact with platelets and fibrinogen to form clots that further facilitate adhesion and spreading of the cancer cells to the endothelium of pulmonary vessels.
The extravasation of circulating tumor cells in the host organ requires successive adhesive interactions between endothelial cells and their ligands or counter-receptors present on the cancer cells. Thus, the specificity of binding between E-selectin and its ligands determine the organ selectivity in cancer metastasis.
Typically, the cancer cell/endothelial cell interactions imply first a selectin-mediated initial attachment and rolling of the circulating cancer cells on the endothelium. The rolling cancer cells then become activated by locally released chemokines present at the surface of endothelial cells. This triggers the activation of integrins from the cancer cells allowing their firmer adhesion to members of the Ig-CAM family such as ICAM, initiating the transendothelial migration and extravasation processes. The culture supernatants of cancer cells can trigger the expression of E-selectin by endothelial cells suggesting that cancer cells may release by themselves cytokines such as TNF-α, IL-1β or INF-γ that will directly activate endothelial cells to express E-selectin, P-selectin, ICAM-2 or VCAM.
Adhesion of colon cancer cells to endothelial cells expressing E-selectin induces a reverse signaling in the cancer cells that increases their motile potential, and a forward signaling in the endothelial cells that increases interendothelial permeability and enables extravasation. For example, adhesion of colon carcinoma cells to endothelial cells involves the binding of E- selectin on endothelial cells to death receptor-3 (DR3) on cancer cells. This interaction induces the reverse activation of p38 and ERK MAP kinases in cancer cells, which increases their motile and survival potentials. Reciprocally, the interaction between DR3 and E-selectin triggers the forward activation of the same MAP kinase pathways in endothelial cells. This results in myosin-light chain (MLC)-mediated cell retraction and in dissociation of the VE-cadherin/β-catenin complex and thereby destruction of adherens junctions leading to increased endothelial permeability and extravasation of cancer cells.
The process of E-selectin and endothelial adhesion receptor-mediated metastasis may be local. In particular, increased hepatic local metastasis of B16F1 melanoma cells is observed following exogenous IL-1a administration, which results from an increased vascular adhesion receptor expression, including E-selectin, VCAM-1 and ICAM-1, and tumor cell arrest in terminal portal venules.
Critical illness polyneuromyopathy
In cases of elevated blood glucose levels, such as in sepsis, E-selectin expression is higher than normal, resulting in greater microvascular permeability. The greater permeability leads to edema (swelling) of the skeletal endothelium (blood vessel linings), resulting in skeletal muscle ischemia (restricted blood supply) and eventually necrosis (cell death). This underlying pathology is the cause of the symptomatic disease critical illness polyneuromyopathy (CIPNM). Traditional Chinese herbal medicines, like berberine downregulate E-selectin.
Study shows the adherence of porphyromonas gingivalis to human umbilical vein endothelial cells increases with the induction of E-selectin expression by TNF-α. An antibody to E-selectin and sialyl LewisX suppressed P. gingivalis adherence to stimulated HUVECs. P. gingivalis mutants lacking OmpA-like proteins Pgm6/7 had reduced adherence to stimulated HUVECs, but fimbriae-deficient mutants were not affected. E-selecin-mediated P. gingivalis adherence activated endothelial exocytosis. These results suggest that the interaction between host E-selectin and pathogen Pgm6/7 mediates P. gingivalis adherence to endothelial cells and may trigger vascular inflammation.
Acute coronary syndrome
The immunohistochemical expressions of E-selectin and PECAM-1 were significantly increased at intima in vulnerable plaques of acute coronary syndrome (ACS) group, especially in neovascular endothelial cells, and positively correlated with inflammatory cell density, suggesting that PECAM-1 and E-selectin might play an important role in inflammatory reaction and development of vulnerable plaque. E-selectin Ser128Arg polymorphism is associated with ACS, and it might be a risk factor for ACS.
Smoking is highly correlated with enhanced likelihood of atherosclerosis by inducing endothelial dysfunction. In endothelial cells, various cell-adhesion molecules including E-selectin, are shown to be upregulated upon exposure to nicotine, the addictive component of tobacco smoke. Nicotine-stimulated adhesion of monocytes to endothelial cells is dependent on the activation of α7-nAChRs, β-Arr1 and cSrc regulated increase in E2F1-mediated transcription of E-selectin gene. Therefore, agents such as RRD-251 that can target activity of E2F1 may have potential therapeutic benefit against cigarette smoke induced atherosclerosis.
It's also found that E-selectin expression increased in human ruptured cerebral aneurysm tissues. E-selectin might be an important factor involved in the process of cerebral aneurysm formation and rupture, by promoting inflammation and weakening cerebral artery walls.
As a biomarker
- Collins T, Williams A, Johnston GI, Kim J, Eddy R, Shows T, Gimbrone MA, Bevilacqua MP (February 1991). "Structure and chromosomal location of the gene for endothelial-leukocyte adhesion molecule 1". J. Biol. Chem. 266 (4): 2466–73. PMID 1703529.
- Graves BJ, Crowther RL, Chandran C, Rumberger JM, Li S, Huang KS, Presky DH, Familletti PC, Wolitzky BA, Burns DK (February 1994). "Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains". Nature 367 (6463): 532–8. doi:10.1038/367532a0. PMID 7509040.
- Somers WS, Tang J, Shaw GD, Camphausen RT (October 2000). "Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1". Cell 103 (3): 467–79. doi:10.1016/S0092-8674(00)00138-0. PMID 11081633.
- Cummings RD (2008). "Selectins". In Varki A, Cummings RD,Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, and Etzler ME. Essentials of Glycobiology (2nd ed.). Plainview, N.Y: Cold Spring Harbor Laboratory Press. ISBN 0-87969-770-9.
- Janeway C (2005). Immunobiology: the immune system in health and disease. New York: Garland Science. ISBN 0-8153-4101-6.
- Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM, Ahern TJ, Buurman WA (December 1992). "E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro". Immunology 77 (4): 543–9. PMC 1421640. PMID 1283598.
- Huang RB, Eniola-Adefeso O (2012). "Shear stress modulation of IL-1β-induced E-selectin expression in human endothelial cells". PLOS ONE 7 (2): e31874. doi:10.1371/journal.pone.0031874. PMC 3286450. PMID 22384091.
- Andrade CM, Sá MF, Toloi MR (April 2012). "Effects of phytoestrogens derived from soy bean on expression of adhesion molecules on HUVEC". Climacteric 15 (2): 186–94. doi:10.3109/13697137.2011.582970. PMID 22066752.
- Robbins SL, Cotran RS, Kumar V, Collins T (1999). Robbins pathologic basis of disease. Philadelphia: WB Saunders. ISBN 0-7216-7335-X.
- Zou X, Shinde Patil VR, Dagia NM, Smith LA, Wargo MJ, Interliggi KA, Lloyd CM, Tees DF, Walcheck B, Lawrence MB, Goetz DJ (August 2005). "PSGL-1 derived from human neutrophils is a high-efficiency ligand for endothelium-expressed E-selectin under flow". Am. J. Physiol., Cell Physiol. 289 (2): C415–24. doi:10.1152/ajpcell.00289.2004. PMID 15814589.
- Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N (May 2004). "Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis". Cancer Sci. 95 (5): 377–84. doi:10.1111/j.1349-7006.2004.tb03219.x. PMID 15132763.
- Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, Pienta KJ, Kutok JL, Rubin MA (July 2005). "Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells". Cancer Res. 65 (13): 5750–60. doi:10.1158/0008-5472.CAN-04-4653. PMC 1472661. PMID 15994950.
- Gout S, Tremblay PL, Huot J (2008). "Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis". Clin. Exp. Metastasis 25 (4): 335–44. doi:10.1007/s10585-007-9096-4. PMID 17891461.
- Shirure VS, Liu T, Delgadillo LF, et. al. "CD44 variant isoforms expressed by breast cancer cells are functional E-selectin ligands under flow conditions". American Journal of Physiology-Cell Physiology 308 (1): C68–C78. doi:10.1152/ajpcell.00094.2014.
- Shirure VS, Reynolds NM, and Burdick MM. "Mac-2 binding protein is a novel E-selectin ligand expressed by breast cancer cells". PLOS ONE 7 (9): e44529. doi:10.1016/j.bbrc.2011.02.061.
- Shirure VS, Henson KA , Schnaar RL, Nimrichter L, Burdick MM. "Gangliosides expressed on breast cancer cells are E-selectin ligands". Biochemical and Biophysical Research Communications 406 (3): 423–429. doi:10.1016/j.bbrc.2011.02.061.
- Nimrichter L, Burdick MM, Aoki K, Laroy W, Fierro MA, Hudson SA, Von Seggern CE, Cotter RJ, Bochner BS, Tiemeyer M, Konstantopoulos K, Schnaar RL (November 2008). "E-selectin receptors on human leukocytes". Blood 112 (9): 3744–52. doi:10.1182/blood-2008-04-149641. PMC 2572800. PMID 18579791.
- Nicolson GL (November 1988). "Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites". Biochim. Biophys. Acta 948 (2): 175–224. doi:10.1016/0304-419X(88)90010-8. PMID 3052592.
- Walzog B, Gaehtgens P (June 2000). "Adhesion Molecules: The Path to a New Understanding of Acute Inflammation". News Physiol. Sci. 15: 107–113. PMID 11390891.
- Wang HH, Qiu H, Qi K, Orr FW (2005). "Current views concerning the influences of murine hepatic endothelial adhesive and cytotoxic properties on interactions between metastatic tumor cells and the liver". Comp Hepatol 4: 8. doi:10.1186/1476-5926-4-8. PMC 1334213. PMID 16336680.
- Visser LH (November 2006). "Critical illness polyneuropathy and myopathy: clinical features, risk factors and prognosis". Eur. J. Neurol. 13 (11): 1203–12. doi:10.1111/j.1468-1331.2006.01498.x. PMID 17038033.
- Hu Y, Chen X, Duan H, Hu Y, Mu X (2009). "Chinese herbal medicinal ingredients inhibit secretion of IL-6, IL-8, E-selectin and TXB2 in LPS-induced rat intestinal microvascular endothelial cells". Immunopharmacol Immunotoxicol 31 (4): 550–5. doi:10.3109/08923970902814129. PMID 19874221.
- Komatsu T, Nagano K, Sugiura S, Hagiwara M, Tanigawa N, Abiko Y, Yoshimura F, Furuichi Y, Matsushita K (April 2012). "E-selectin Mediates Porphyromonas gingivalis Adherence to Human Endothelial Cells". Infect Immun 80 (7): 2570–6. doi:10.1128/IAI.06098-11. PMID 22508864.
- Fang F, Zhang W, Yang L, Wang Z, Liu DG (December 2011). "[PECAM-1 and E-selectin expression in vulnerable plague and their relationships to myocardial Leu125Val polymorphism of PECAM-1 and Ser128Arg polymorphism of E-selectin in patients with acute coronary syndrome]". Zhonghua Xin Xue Guan Bing Za Zhi (in Chinese) 39 (12): 1110–6. PMID 22336504.
- Alamanda V, Singh S, Lawrence NJ, Chellappan SP (February 2012). "Nicotine-mediated induction of E-selectin in aortic endothelial cells requires Src kinase and E2F1 transcriptional activity". Biochem. Biophys. Res. Commun. 418 (1): 56–61. doi:10.1016/j.bbrc.2011.12.127. PMC 3273677. PMID 22240023.
- Jia W, Wang R, Zhao J, Liu IY, Zhang D, Wang X, Han X (November 2011). "E-selectin expression increased in human ruptured cerebral aneurysm tissues". Can J Neurol Sci 38 (6): 858–62. PMID 22030423.
- Sato H, Usuda N, Kuroda M, Hashimoto S, Maruta M, Maeda K (November 2010). "Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer". Jpn. J. Clin. Oncol. 40 (11): 1073–80. doi:10.1093/jjco/hyq095. PMID 20576794.